Literature DB >> 24942955

Clostridium difficile infection in hospitalized patients at a Czech tertiary center: analysis of epidemiology, clinical features, and risk factors of fulminant course.

Karel Balihar1, Filip Kozak, Jana Kozeluhova, Vaclav Hejda, Lucie Fremundova, Michal Krcma, Lenka Geigerova, Tamara Bergerova, Martin Matejovic.   

Abstract

OBJECTIVE: Clostridium difficile infection (CDI) has been increasing in incidence, with significant morbidity and mortality, and is subject to geographical and institutional variability. We aimed to characterize epidemiology and clinical manifestations of CDI in a Czech tertiary care center and to identify risk factors of fulminant course.
METHODS: All adult patients hospitalized with primary CDI in a 3-year period were retrospectively identified. Epidemiological and clinically descriptive data were extracted from medical records. Multivariate analysis was used to identify the risk factors of fulminant course. The relationship between incidence of CDI and antibiotic consumption was evaluated.
RESULTS: Overall, 183 CDI patients, median age 67 years, were enrolled. Hospital-acquired CDI was present in 85% of cases. The incidence of CDI was 1/10,000 patient-days. Hospital-acquired CDI hospital mortality was 22.4%. Severe CDI (SCDI) was identified in 15.8% of patients, with 62% mortality. SCDI patients had longer onset of symptoms to diagnosis interval compared with mild CDI (P=0.05). Multivariate analysis showed that SCDI patients were older (P=0.018), and more frequently had abnormal abdominal physical findings (P=0.001), higher inflammatory markers (P<0.001), higher creatinine (P=0.002), and lower albumin (P<0.001) than patients with mild CDI. Analysis of antibiotic consumption at departments with the highest incidence of CDI showed a trend toward higher incidence of CDI associated with penicillin use (P=0.08) and a negative correlation of CDI incidence with nitroimidazoles consumption (P=0.03).
CONCLUSION: CDI is less frequent in the conditions studied compared with literary data; however, the fulminant form has a very high mortality. Delayed recognition and treatment is a crucial determinant of the severity of CDI. The association between CDI and antibiotic consumption is less clear.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24942955     DOI: 10.1097/MEG.0000000000000139

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  5 in total

1.  Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.

Authors:  Zsuzsanna Kurti; Barbara D Lovasz; Michael D Mandel; Zoltan Csima; Petra A Golovics; Bence D Csako; Anna Mohas; Lorant Gönczi; Krisztina B Gecse; Lajos S Kiss; Miklos Szathmari; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

2.  Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.

Authors:  David M Faleck; Hojjat Salmasian; E Yoko Furuya; Elaine L Larson; Julian A Abrams; Daniel E Freedberg
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

3.  Clostridium difficile in western Romania: unfavourable outcome predictors in a hospital for infectious diseases.

Authors:  Ruxandra Laza; Ruxandra Jurac; Alexandru Crişan; Voichiţa Lăzureanu; Monica Licker; Emilian Damian Popovici; Luminiţa Mirela Bădiţoiu
Journal:  BMC Infect Dis       Date:  2015-03-21       Impact factor: 3.090

4.  Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI).

Authors:  Carolin F Manthey; Darja Dranova; Martin Christner; Andreas Drolz; Stefan Kluge; Ansgar W Lohse; Valentin Fuhrmann
Journal:  Crit Care       Date:  2019-12-09       Impact factor: 9.097

5.  Global burden of Clostridium difficile infections: a systematic review and meta-analysis.

Authors:  Evelyn Balsells; Ting Shi; Callum Leese; Iona Lyell; John Burrows; Camilla Wiuff; Harry Campbell; Moe H Kyaw; Harish Nair
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.